Goldshield is in buyout talks
GOLDSHIELD, the generic drugs firm, yesterday confirmed it is in advanced talks with AIT, a buyout alliance that includes the firm’s former chief executive, over a possible takeover.
AIT, formed of pharma firm Neopharm and Goldshield’s ex-boss Ajit Patel, said earlier it was carrying out due diligence on the group. Patel left the firm in 2007 amid a price-fixing case brought against Goldshield by the Serious Fraud Office, which Goldshield won in July 2008. Brewin Dolphin analysts said they expect an offer of 567p per share, compared to the firm’s current price of 405p.